Showing results (181-190 of 249) with videos related to
Sort By:
Pageof 25
Biochemistry|June 7, 2006
Pharmacological characterization of 40 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists and the agouti-related protein (AGRP) antagonistZhimin Xiang, Sally A Litherland, Nicholas B Sorensen, et al.Occupational and Environmental Medicine|January 10, 1998
Allergy risk in an enzyme producing plant: a retrospective follow up studyC R Johnsen, T B Sorensen, A Ingemann Larsen, et al.Biochemistry|July 24, 1979
Dioxygen replacement reaction in myoglobinD Beece, L Eisenstein, H Frauenfelder, et al.Journal of Proteomics|September 13, 2012
Identification and quantification of newly synthesized proteins translationally regulated by YB-1 using a novel Click-SILAC approachSyam Prakash Somasekharan, Nikolay Stoynov, Barak Rotblat, et al.Applied Microbiology and Biotechnology|May 21, 2003
Diversification of exogenous genes in vivo in NeurosporaD E A Catcheside, J P Rasmussen, P J Yeadon, et al.The American Journal of Surgical Pathology|May 29, 2007
Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology GroupDavid M Parham, Stephen J Qualman, Lisa Teot, et al.Seminars in Oncology|August 12, 2009
Sarcomas with spindle cell morphologyPaola Collini, Poul H B Sorensen, Shreyaskumar Patel, et al.Rhinology|October 27, 2018
Propofol sedation in Drug Induced Sedation Endoscopy without an anaesthesiologist â€" a study of safety and feasibilityE Kirkegaard Kiaer, P Tonnesen, H B Sorensen, et al.Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|January 18, 2012
Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experienceJason J Schwartz, Lisa Pappas, Heather F Thiesset, et al.European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancerF Caponigro, C Dittrich, J B Sorensen, et al.Pageof 25